Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | TPMT | P51580 | 1/20 | 0.42 |
| ▸ | MYC | P01106 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.39 |
| ▸ | HPGD | P15428 | 3/20 | 0.39 |
| ▸ | APP | P05067 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | AKR1C3 | P42330 | 2/20 | 0.36 |
| ▸ | AKR1C2 | P52895 | 2/20 | 0.36 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5832803 | 0.85 | TDP1 (0.47) | TDP1MAPTTPMTMYCALDH1A1 | |
| SCHEMBL1919502 | 0.81 | TDP1 (0.50) | TDP1MAPTMYCALDH1A1HSD17B10 | |
| SCHEMBL27598132 | 0.80 | TDP1 (0.46) | TDP1MAPTTPMTALDH1A1HSD17B10 | |
| SCHEMBL1505827 | 0.80 | TDP1 (0.61) | TDP1MAPTALDH1A1HSD17B10POLB | |
| SCHEMBL4309406 | 0.79 | MAPT (0.62) | TDP1MAPTTPMTMYCALDH1A1 | |
| SCHEMBL6474772 | 0.79 | TDP1 (0.58) | TDP1MAPTTPMTMYCALDH1A1 | |
| SCHEMBL28007255 | 0.78 | CYP1A2 (0.44) | TDP1MYCALDH1A1HSD17B10KDM4E | |
| SCHEMBL288168 | 0.78 | TDP1 (0.47) | TDP1MAPTMYCALDH1A1HSD17B10 | |
| SCHEMBL2552082 | 0.78 | TDP1 (0.47) | TDP1MAPTALDH1A1HSD17B10POLB | |
| SCHEMBL26730159 | 0.78 | TDP1 (0.66) | TDP1MAPTTPMTALDH1A1HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10000471-B2 | Pyrazole P38 map kinase inhibitors | RESPIVERT LIMITED (GB) | 2018-06-19 | — | — | US | disclosed |
| US-20170362208-A1 | NOVEL COMPOUNDS | RESPIVERT LIMITED (GB) | 2017-12-21 | — | — | US | disclosed |
| US-9771354-B2 | Pyrazole p38 map kinase inhibitors | RESPIVERT LTD. (GB) | 2017-09-26 | — | — | US | disclosed |
| US-20160130256-A1 | NOVEL COMPOUNDS | RESPIVERT LIMITED (GB) | 2016-05-12 | — | — | US | disclosed |
| EP-2556065-B1 | PYRAZOLE P38 MAP KINASE INHIBITORS | RESPIVERT LTD (GB) | 2014-12-17 | — | — | EP | disclosed |
| US-20140323511-A1 | CHEMOTHERAPEUTIC FOR INDUCING AN MSH2 DEPENDENT APOPTOTIC PATHWAY | WAKE FOREST UNIVERSITY HEALTH SCIENCES (US) | 2014-10-30 | — | — | US | disclosed |
| EP-2556065-A1 | PYRAZOLE P38 MAP KINASE INHIBITORS | Respivert Limited (GB) | 2013-02-13 | — | — | EP | disclosed |
| US-20130029990-A1 | PYRAZOLE P38 MAP KINASE INHIBITORS | RESPIVERT LTD. (GB) | 2013-01-31 | — | — | US | disclosed |
| WO-2011121366-A1 | PYRAZOLE P38 MAP KINASE INHIBITORS | RESPIVERT LIMITED (GB) | 2011-10-06 | — | — | WO | disclosed |
| US-5244771-A | Bridged indicator dyes used as light-absorbing, pH-sensitive optical filter agents in diffusion transfer | POLAROID CORPORATION (US) | 1993-09-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170362208-A1 | NOVEL COMPOUNDS | ARG1, IL1B, LTB4R | TDP1 2420/4885MAPT 2621/4885TPMT 847/4885 |
| US-20140323511-A1 | CHEMOTHERAPEUTIC FOR INDUCING AN MSH2 DEPENDENT APOPTOTIC PATHWAY | MSH2, MSH6, MCL1 | TDP1 858/4885MAPT 4060/4885TPMT 597/4885 |
| US-10000471-B2 | Pyrazole P38 map kinase inhibitors | MAPK1, MAP3K1, MAPK3 | TDP1 940/4885MAPT 1600/4885TPMT 493/4885 |
| US-20160130256-A1 | NOVEL COMPOUNDS | ARG1, IL1B, LTB4R | TDP1 2420/4885MAPT 2621/4885TPMT 847/4885 |
| US-20130029990-A1 | PYRAZOLE P38 MAP KINASE INHIBITORS | MAPK1, MAP3K1, MAPK3 | TDP1 1005/4885MAPT 1747/4885TPMT 475/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.